Communicate with Supplier? Supplier
What can I do for you?
Contact Supplier


Send Inquiry

Your message must be between 20-8000 characters
High Flow oxygen therapy Hifnet Respircare

High Flow oxygen therapy Hifnet Respircare

Payment Type: L/C,T/T
Min. Order: 1 Piece/Pieces

Contact Now Add to Basket

Basic Info

    Model No.: HUMID BH

Additional Info

    Productivity: 1,000/month

    Brand: respircare

    Transportation: Ocean,Land,Air

    Supply Ability: 3000/month

    Certificate: CE

    HS Code: 9019200090

    Port: Dalian,Shanghai,Beijing

Product Description

High Flow oxygen therapy Hifnet Respircare

The effect of high-flow nasal catheter humidification oxygen therapy (HHFNC) on the respiratory-related parameters and adverse events of the transportation of critically ill children in the hospital. Methods 185 critically ill children who need to be transferred from the emergency room to the pediatric ward were randomly divided into treatment groups 94 cases and 91 cases in the control group. The treatment group was given HHFNC, and the control group was given oxygen via a humidified bottle nasal catheter or face mask. The respiratory frequency, blood oxygen saturation (SPO2), and arterial blood oxygen partial pressure were compared before and after the transfer of the two groups. (Pa O2), changes in arterial partial pressure of carbon dioxide (PaCO2) and other indicators, as well as the incidence of transport adverse events and the rate of tracheal intubation within 24 hours of reaching the children’s ward. Results Before transport, the respiratory rate of the two groups of children, SPO2, PaO2, There was no statistically significant difference in PaCO2 (P>0.05). When transported to the pediatric ward through the hospital, the above indicators in the treatment group were not statistically different from those before transport, but the SPO2 and PaO2 of the treatment group were significantly higher than those of the control group. The respiratory frequency, PaCO2 It was significantly lower than the control group (P<0.05). 15 cases (16.0%) in the treatment group underwent tracheal intubation within 24 hours of arriving in the pediatric ward, which was significantly lower than 28 cases (30.8%) in the control group, and the difference was statistically significant ( P<0.05); there was no statistically significant difference in the incidence of adverse events during the transfer process between the two groups of children (P>0.05). Conclusion The use of HHFNC for respiratory support during the transfer process of critically ill children can effectively improve the oxygenation of the children. And ventilation function, reduce the risk of transportation.

Main Features:
Delivering high flows , high concentration ,close to 100% relative humidity of air/oxygen mixtures to spontaneously breathing patients, is considered to have a number of following effects:

1. Keep constant、precise、high FiO2 and improve the alveolar ventilation
2. Improve the efficiency of breathing by reduction of anatomical dead space and replacing it with oxygen-enriched gas in the upper airway.
3. Low levels of PEEP may contribute to collapsed alveolar recruitment
4. Good humidity promote effective from the sputum and mucociliary clearance to reduce the risk of infection
5. More comfort , Better tolerance and Greater respiratory compliance in the patients.
High Flow Nasal Cannula Devices

Clinical application value
1. ICU emergency mild and moderate acute respiratory failure(hypoxic Non-CO2 retention )
Improve breathing difficulty and the effect of improving oxygenation is obvious.
The rate of intubation and mortality were significantly lower than that of noninvasive ventilation and standard oxygen therapy.

2. A new option from the creative withdrawal machine.
The drone fights and reduces the reintubation rate.

3. Acute heart failure or cardiogenic pulmonary edema
Improve oxygenation and reduce cardiac load.

4. Hypoxic patients assist bronchoscopy, transesophageal ultrasonography and digestive endoscopy.
Added an effective oxygen therapy.

5. Chronic respiratory failure
Improve ciliary activity, promote sputum discharge, reduce the chance of infection.

6. Palliative treatment
New options for end-stage patients who reject intubation and resuscitation.

7. Cardiothoracic surgery is associated with a risk of respiratory failure.
The results were comparable to non-invasive ventilation, but the patient was comfortable.

Power supply
Flow setting range
●Low Flow Mode:2-25L /Min temp:34°C
●High Flow Mode:10-80L/Min
Temperature Control
31°C ,34°C ,37°C
Oxygen% Measure
21 %-100%
FiO2 Control
Auto proportional valve control
Alarm parameters
●Low oxygen concentration alarm
●High oxygen concentration alarm
●Ambient temp alarm
●Choke alarm
●Alarm recovery
Recommended Ambient Temp 18-28°C
IEC/EN 6060-1, IEC/ EN 60601-1-2; IS08185

Our Company

Shenyang Maisi Medical Technology Co., Ltd. is a high-tech emerging modern enterprise specializing in the development, production, sales and service of respiratory diagnosis and treatment and electronic products. It is a domestic company with core technology covering 2 major respiratory therapy equipment.

The company is headquartered in Hunnan High-tech Development Zone, Shenyang City, Liaoning Province. The company covers an area of more than 6000 square meters. The current main products are high-flow respiratory humidification therapy equipment (HFNC), non-invasive ventilation therapy equipment (BiPAP AutoBiPAP and Auto-CPAP) . The company's products have passed the US FDA, EU CE, RoHS and South Korea GMP certification, and strictly implement ISO13485, ISO9001 and national and industry related standards in every link of development and production. The product quality is stable and reliable, and has been universally recognized by customers all over the world.

The company's technical core backbone is composed of a team of technical experts from the fields of domestic information technology, automation control, machinery manufacturing and medical technology. The company has good cooperation with Air Force Aviation Medical Research Institute, China Medical University and other well-known domestic units.

Since its founding, Maxx Medical has forged ahead and has become a brand influential enterprise in the field of respiratory support in China. To create the future and not forget the original intention, Max Medical will strive to become an excellent brand of respiratory support in China.

rms medical

Maisi has many years of experience in product development in the respiratory therapy industry, and has won a number of patents. The perfect after-sales service has brought us more and more users and sold to more than a dozen countries and regions. Based on the principle of good quality and customer first, we will dedicate effective and reliable products to customers with superb and innovative technical strength, advanced equipment and good service attitude.

our company

Use advanced technology to serve clinical respiratory medicine and seek welfare for patients with respiratory diseases.
With professional integrity, we provide advanced, convenient and economical sleep and breathing treatment programs for patients with respiratory diseases.



1. Are you a manufacturer or trading company?
RE:We are a manufacturer specilized in respirtory products,including Noninvasive Ventilators, HFNC and Oxygen Concentrators.

2. Do you have any certification?
RE:We are CE and EN ISO 13485 approved and FDA is in application and will be available in near future.

3. How long is your product warranty period?
RE:2 years.

Looking for ideal Nasal Cannula Oxygen Delivery Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the High Flow Oxygen Devices are quality guaranteed. We are China Origin Factory of High Flow Oxygen Tubing. If you have any question, please feel free to contact us.

Product Categories : High Flow Nasal Cannula > HUMID BH

Email to this supplier

Your message must be between 20-8000 characters

Related Products List